Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 36

Results For "road"

1549 News Found

NIPER Raebareli–Roche tie-up signals big push for India’s pharma innovation future
R&D | March 20, 2026

NIPER Raebareli–Roche tie-up signals big push for India’s pharma innovation future

The partnership is designed to close the gap between classroom learning and real-world pharmaceutical practice


LANXESS marks 40 yrs of animal disease defense 'Virkon S'
News | March 20, 2026

LANXESS marks 40 yrs of animal disease defense 'Virkon S'

A disinfectant credited with helping contain some of the world’s most dangerous livestock diseases is marking a major milestone


Merck’s SPARK program hits 10-year milestone, sets sights on reaching 75 million students
News | March 19, 2026

Merck’s SPARK program hits 10-year milestone, sets sights on reaching 75 million students

SPARK has extended its influence to an additional 9.47 million students worldwide


Zydus, Lupin join forces to expand access to semaglutide in India
News | March 18, 2026

Zydus, Lupin join forces to expand access to semaglutide in India

The deal also includes upfront licensing fees and milestone-based payments from Lupin to Zydus


Allergan Aesthetics unveils ‘Skin Quality Index’ to close gap between patients & doctors
Healthcare | March 17, 2026

Allergan Aesthetics unveils ‘Skin Quality Index’ to close gap between patients & doctors

The framework introduces 15 consensus terms and definitions grouped across four core dimensions of skin health


Aptar Pharma teams up with COVIRIX Medical to explore next-generation antiviral inhaler
R&D | March 16, 2026

Aptar Pharma teams up with COVIRIX Medical to explore next-generation antiviral inhaler

COVIRIX Medical says its broad-spectrum antiviral portfolio has already shown positive virology results against key pandemic threats


GSK expands RSV vaccine to younger adults in US, targeting high-risk 18–49 age group
News | March 16, 2026

GSK expands RSV vaccine to younger adults in US, targeting high-risk 18–49 age group

Previously, Arexvy was authorized for adults 60 and older, and for those 50–59 with heightened risk


C2N Diagnostics expands Alzheimer’s blood test to South Korea via BeauBrain partnership
News | March 16, 2026

C2N Diagnostics expands Alzheimer’s blood test to South Korea via BeauBrain partnership

Under the agreement, healthcare professionals in the country will gain access to C2N’s PrecivityAD2 blood test


First patient dosed in trial of novel drug targeting limb-threatening artery disease
News | March 16, 2026

First patient dosed in trial of novel drug targeting limb-threatening artery disease

The trial will enroll up to 42 patients in Finland across four cohorts